Jade Biosciences Inc
JBIOHealthcare|Biotechnology|USA
$20.94
-1.54 (-6.85%)
Tangible Book
$6.01
About
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Stock Price
+99.0%(1Y)
Pipeline Summary
6 total trials3
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Active: 1Recruiting: 3Unknown: 1NOT_YET_RECRUITING: 1
Active Trials (4)
A Phase 1 Study of JADE101 in Healthy Participants
NCT07059312Healthy Volunteers
Phase 1Active
Enrollment: 32 participants
A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
NCT07533955Rhematoid Arthritis
Phase 1Recruiting
Enrollment: 36 participants
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
NCT07525947Healthy Volunteers (HV)
Phase 1Recruiting
Enrollment: 40 participants
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
NCT07541287IgA Nephropathy
Phase 2Recruiting
Enrollment: 30 participants
BioScore
3.6/10
Cautious
Ownership
Recent Insider Trades
Frohlich TomBUY
2025-05-166,000 shares @ $7.4
Recent News
2026-06-15 13:37:32
Data last updated: Jul 13, 2026, 12:47 PM